Mississauga, ON – September 25, 2026 -- Kye Pharmaceuticals ranked No. 105 on Report on Business magazine's 2026 list of Canada's Top Growing Companies, posting three-year revenue growth of 264%.
Kye secures second consecutive year on the Globe and Mail growth ranking
The Mississauga, Ontario-based specialty pharmaceutical company previously appeared on the 2025 edition of the list, marking its second straight year of recognition. The 2026 ranking included 376 companies in total, each qualifying through a voluntary application process and targeted revenue thresholds based on three-year growth performance.
CEO ties growth to expanded patient access in Canada
John McKendry, President & CEO at Kye Pharmaceuticals, attributed the company's growth trajectory to its focus on delivering medicines for areas of high unmet medical need across Canada. Kye's portfolio spans cardiology, psychiatry, pediatrics, rare diseases, neuromuscular conditions, hematology, and neurology.
Full 2026 rankings published in October issue
The complete list of 2026 winners, along with editorial coverage, appears in the October issue of Report on Business magazine and online via The Globe and Mail. Dawn Calleja, editor of Report on Business magazine, said the annual ranking highlights the innovation and resilience of businesses across Canada. Andrew Saunders, president and CEO of The Globe and Mail, said this year's honorees demonstrated an extraordinary ability to adapt and grow amid ongoing economic change.